Literature DB >> 18353725

Toward specific functions of poly(ADP-ribose) polymerase-2.

José Yélamos1, Valérie Schreiber, Françoise Dantzer.   

Abstract

Poly(ADP-ribose) polymerase-2 (PARP-2) belongs to a family of enzymes that catalyze poly(ADP-ribosyl)ation of proteins. PARP-1 and PARP-2 are so far the only PARP enzymes whose catalytic activity has been shown to be induced by DNA-strand breaks, providing strong support for key shared functions in the cellular response to DNA damage. Accordingly, clinical trials for cancer, using PARP inhibitors that target the conserved catalytic domain of PARP proteins, are now ongoing. However, recent data suggest unique functions for PARP-2 in specific processes, such as genome surveillance, spermatogenesis, adipogenesis and T cell development. Understanding these physiological roles might provide invaluable clues to the rational development and exploitation of specific PARP-2 inhibitor drugs in a clinical setting and the design of new therapeutic approaches in different pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353725     DOI: 10.1016/j.molmed.2008.02.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  56 in total

1.  Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.

Authors:  Wen-Hua Chen; Shan-Shan Song; Ming-Hui Qi; Xia-Juan Huan; Ying-Qing Wang; Hualiang Jiang; Jian Ding; Guo-Bin Ren; Ze-Hong Miao; Jian Li
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 3.  PARP inhibitor treatment in ovarian and breast cancer.

Authors:  Marcie K Weil; Alice P Chen
Journal:  Curr Probl Cancer       Date:  2011 Jan-Feb       Impact factor: 3.187

Review 4.  PARP inhibition: PARP1 and beyond.

Authors:  Michèle Rouleau; Anand Patel; Michael J Hendzel; Scott H Kaufmann; Guy G Poirier
Journal:  Nat Rev Cancer       Date:  2010-03-04       Impact factor: 60.716

Review 5.  Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.

Authors:  Jin-xue He; Chun-hao Yang; Ze-hong Miao
Journal:  Acta Pharmacol Sin       Date:  2010-08-02       Impact factor: 6.150

6.  Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease.

Authors:  Hanna Shevalye; Yury Maksimchyk; Pierre Watcho; Irina G Obrosova
Journal:  Biochim Biophys Acta       Date:  2010-07-16

7.  Targeting metastatic upper gastrointestinal adenocarcinomas.

Authors:  Jennifer L Spratlin; Quincy Chu; Sheryl Koski; Karen King; Karen Mulder
Journal:  World J Clin Oncol       Date:  2011-03-10

Review 8.  Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Authors:  Frédérique Mégnin-Chanet; Marc A Bollet; Janet Hall
Journal:  Cell Mol Life Sci       Date:  2010-08-20       Impact factor: 9.261

9.  Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites.

Authors:  Matthias Altmeyer; Simon Messner; Paul O Hassa; Monika Fey; Michael O Hottiger
Journal:  Nucleic Acids Res       Date:  2009-04-16       Impact factor: 16.971

10.  Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination.

Authors:  Isabelle Robert; Françoise Dantzer; Bernardo Reina-San-Martin
Journal:  J Exp Med       Date:  2009-04-13       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.